Analyst: Novartis's Kesimpta sales exceeded expectations
Genmab may upgrade its financial guidance after the biotech company's partner made more sales than expected of sclerosis drug Kesimpta, a Sydbank analyst predicts.
by marketwire, translated by catherine brett
Novartis's sales of Genmab-developed drug Kesimpta were better than both the analyst consensus estimate and Sydbank's prediction, which could mean an upgrade to its financial guidance is on the way from Genmab, Senior Analyst Søren Løntoft Hansen states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis beats expectations for third quarter
For subscribers
